{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:39:28Z","timestamp":1787009968570,"version":"build-2736575974"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1097\/fpc.0000000000000056","type":"journal-article","created":{"date-parts":[[2014,5,12]],"date-time":"2014-05-12T10:10:10Z","timestamp":1399889410000},"page":"331-339","source":"Crossref","is-referenced-by-count":35,"title":["COMT gene and risk for Parkinson\u2019s disease"],"prefix":"10.1097","volume":"24","author":[{"given":"F\u00e9lix J.","family":"Jim\u00e9nez-Jim\u00e9nez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hortensia","family":"Alonso-Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Garc\u00eda-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.G.","family":"Ag\u00fandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210213","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1517\/17425255.2013.789018","article-title":"Anti-Parkinsons disease drugs and pharmacogenetic considerations.","volume":"9","author":"Agundez","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R4-1-20210213","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00008571-199702000-00009","article-title":"Genetic polymorphism of catechol-O-methyltransferase (COMT): correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland.","volume":"7","author":"Syvanen","year":"1997","journal-title":"Pharmacogenetics"},{"key":"R6-1-20210213","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/mds.870120325","article-title":"GA1947 polymorphism in catechol-O-methyltransferase (COMT) gene in Parkinsons disease.","volume":"12","author":"Xie","year":"1997","journal-title":"Mov Disord"},{"key":"R7-1-20210213","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/BF01294732","article-title":"Catechol-O-methyltransferase genotype and susceptibility to Parkinsons disease in Japan. Short communication.","volume":"104","author":"Yoritaka","year":"1997","journal-title":"J Neural Transm"},{"key":"R8-1-20210213","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/1531-8257(200009)15:5<1013::AID-MDS1040>3.0.CO;2-S","article-title":"Meta-analysis of polymorphism of the catechol-O-methyltransferase gene in relation to the etiology of Parkinsons disease in Japan.","volume":"15","author":"Mizuta","year":"2000","journal-title":"Mov Disord"},{"key":"R9-1-20210213","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0304-3940(00)01749-3","article-title":"Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinsons disease.","volume":"298","author":"Lee","year":"2001","journal-title":"Neurosci Lett"},{"key":"R10-1-20210213","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1212\/WNL.56.3.375","article-title":"The COMT L allele modifies the association between MAOB polymorphism and PD in Taiwanese.","volume":"56","author":"Wu","year":"2001","journal-title":"Neurology"},{"key":"R14-1-20210213","first-page":"440","article-title":"Catecholamine-O-methyltransferase (COMT) gene polymorphism and the risk of Parkinsons disease in Shanghai Han population.","volume":"19","author":"Xu","year":"2002","journal-title":"Chin J Med Genet"},{"key":"R15-1-20210213","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/mds.10430","article-title":"Lack of effect of polymorphisms in dopamine metabolism related genes on imaging of TRODAT-1 in striatum of asymptomatic volunteers and patients with Parkinsons disease.","volume":"18","author":"Lynch","year":"2003","journal-title":"Mov Disord"},{"key":"R16-1-20210213","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000074637","article-title":"Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinsons disease.","volume":"48","author":"Watanabe","year":"2003","journal-title":"Neuropsychobiology"},{"key":"R17-1-20210213","first-page":"743","article-title":"Correlation between the genetic polymorphism of dopamine metabolic enzymes and the genetic susceptibility of Parkinsons disease.","volume":"25","author":"Ming","year":"2005","journal-title":"J Gerontol"},{"key":"R18-1-20210213","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1111\/j.1468-1331.2008.02186.x","article-title":"No association of the Val158Met COMT polymorphism with Parkinsons disease in the Greek population.","volume":"15","author":"Kalinderi","year":"2008","journal-title":"Eur J Neurol"},{"key":"R19-1-20210213","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/FPC.0b013e328306c2f2","article-title":"The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinsons disease, levodopa treatment response, and complications.","volume":"18","author":"Bialecka","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"R20-1-20210213","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.neurobiolaging.2008.07.009","article-title":"The val158met COMT polymorphisms effect on atrophy in healthy aging and Parkinsons disease.","volume":"31","author":"Rowe","year":"2010","journal-title":"Neurobiol Aging"},{"key":"R22-1-20210213","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s12041-010-0030-1","article-title":"Exploration of genetic susceptibility factors for Parkinsons disease in a South American sample.","volume":"89","author":"Benitez","year":"2010","journal-title":"J Genet"},{"key":"R24-1-20210213","doi-asserted-by":"crossref","first-page":"382","DOI":"10.5114\/fn.2012.32368","article-title":"Association of monoamine oxidase B and catechol-O-methyltransferase polymorphisms with sporadic Parkinsons disease in an Iranian population.","volume":"50","author":"Torkaman-Boutorabi","year":"2012","journal-title":"Folia Neuropathol"},{"key":"R25-1-20210213","first-page":"279","article-title":"An association study between genetic variants at mu-opioid receptor, dopamine transporter, catechol-O-methyltransferase, and dopamine genes and risk of Parkinsons disease.","volume":"18","author":"Shih","year":"2013","journal-title":"Neurol Asia"},{"key":"R28-1-20210213","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-2288-6-31","article-title":"Meta-DiSc: a software for meta-analysis of test accuracy data.","volume":"6","author":"Zamora","year":"2006","journal-title":"BMC Med Res Methodol"},{"key":"R29-1-20210213","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies.","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"R30-1-20210213","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R31-1-20210213","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2307\/3001666","article-title":"The combination of estimates from different experiments.","volume":"10","author":"Cochran","year":"1954","journal-title":"Biometrics"},{"key":"R32-1-20210213","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"Br Med J"},{"key":"R33-1-20210213","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ana.10079","article-title":"Association studies of multiple candidate genes for Parkinsons disease using single nucleotide polymorphisms.","volume":"51","author":"Momose","year":"2002","journal-title":"Ann Neurol"},{"key":"R39-1-20210213","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.parkreldis.2006.10.006","article-title":"Polymorphisms of catechol-O-methyltransferase (COMT), monoamine oxidase B (MAOB), N-acetyl-transferase 2 (NAT2) and cytochrome P450 2D6 (CYP2D6) gene in patients with early onset of Parkinsons disease.","volume":"13","author":"Bialecka","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"key":"R42-1-20210213","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.neulet.2010.06.085","article-title":"Smoking, genes encoding dopamine pathway and risk for Parkinsons disease.","volume":"482","author":"Gu","year":"2010","journal-title":"Neurosci Lett"},{"key":"R43-1-20210213","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00002826-200005000-00003","article-title":"The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinsons disease.","volume":"23","author":"Chong","year":"2000","journal-title":"Clin Neuropharmacol"},{"key":"R44-1-20210213","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/mds.20410","article-title":"Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinsons disease.","volume":"20","author":"Contin","year":"2005","journal-title":"Mov Disord"},{"key":"R45-1-20210213","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/mds.23805","article-title":"Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinsons disease.","volume":"27","author":"de Lau","year":"2012","journal-title":"Mov Disord"},{"key":"R46-1-20210213","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1600-0404.2004.00315.x","article-title":"The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinsons disease.","volume":"110","author":"Bialecka","year":"2004","journal-title":"Acta Neurol Scand"},{"key":"R47-1-20210213","doi-asserted-by":"crossref","first-page":"272","DOI":"10.55782\/ane-2012-1900","article-title":"The catechol-O-methyltransferase and monoamine oxidase B polymorphisms and levodopa therapy in the Iranian patients with sporadic Parkinsons disease.","volume":"72","author":"Torkaman-Boutorabi","year":"2012","journal-title":"Acta Neurobiol Exp (Wars)"},{"key":"R48-1-20210213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajmg.b.30198","article-title":"Functional COMT variant predicts response to high dose pyridoxine in Parkinsons disease.","volume":"137B","author":"Tan","year":"2005","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"R49-1-20210213","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1212\/WNL.58.4.564","article-title":"COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinsons disease.","volume":"58","author":"Lee","year":"2002","journal-title":"Neurology"},{"key":"R52-1-20210213","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.parkreldis.2011.10.019","article-title":"Role of genetic polymorphisms of the dopaminergic system in Parkinsons disease patients with impulse control disorders.","volume":"18","author":"Vallelunga","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"R53-1-20210213","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1523\/JNEUROSCI.0774-07.2007","article-title":"Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinsons disease.","volume":"27","author":"Williams-Gray","year":"2007","journal-title":"J Neurosci"},{"key":"R55-1-20210213","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/mds.23319","article-title":"Catechol-O-methyltransferase val158met and cognitive function in Parkinsons disease.","volume":"25","author":"Hoogland","year":"2010","journal-title":"Mov Disord"},{"key":"R58-1-20210213","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/00222895.2012.721406","article-title":"Association of catechol-O-methyltransferase polymorphism (Val108158Met) with Parkinsons disease: a meta-analysis.","volume":"44","author":"Wang","year":"2012","journal-title":"J Mot Behav"},{"key":"R59-1-20210213","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4103\/0028-3886.108121","article-title":"The COMT Val158Met polymorphism as an associated risk factor for Parkinsons disease in Asian rather than Caucasian populations.","volume":"61","author":"Lechun","year":"2013","journal-title":"Neurol India"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T12:14:47Z","timestamp":1716725687000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201407000-00001"}},"subtitle":["a systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000056","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}